At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09966 ALPHAMAB-B
Closed The day following the Chung Yeung Festival 10-16 16:08:16
6.900
+0.225
+3.37%
High7.180
Low6.810
Vol1.04M
Open6.810
D1 Closing6.675
Amplitude5.54%
Mkt Cap6.67B
Tradable Cap6.67B
Total Shares966.00M
T/O7.28M
T/O Rate0.11%
Tradable Shares966.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Alphamab Oncology Executes HKD 0.94 Million Share Buyback, Lifts Treasury Stock to 8.09 Million Shares
Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.